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Abstract
Background: Genome-wide association studies (GWAS) have identified several breast cancer susceptibility loci, and one
genetic variant, rs11249433, at 1p11.2 was reported to be associated with breast cancer in European populations. To
explore the genetic variants in this region associated with breast cancer in Chinese women, we conducted a two-stage fine-
mapping study with a total of 1792 breast cancer cases and 1867 controls.
Methodology/Principal Findings: Seven single nucleotide polymorphisms (SNPs) including rs11249433 in a 277 kb region
at 1p11.2 were selected and genotyping was performed by using TaqManH OpenArray
TM Genotyping System for stage 1
samples (878 cases and 900 controls). In stage 2 (914 cases and 967 controls), three SNPs (rs2580520, rs4844616 and
rs11249433) were further selected and genotyped for validation. The results showed that one SNP (rs2580520) located at a
predicted enhancer region of SRGAP2 was consistently associated with a significantly increased risk of breast cancer in a
recessive genetic model [Odds Ratio (OR) = 1.66, 95% confidence interval (CI) = 1.16–2.36 for stage 2 samples; OR = 1.51,
95% CI = 1.16–1.97 for combined samples, respectively]. However, no significant association was observed between
rs11249433 and breast cancer risk in this Chinese population (dominant genetic model in combined samples: OR = 1.20,
95% CI = 0.92–1.57).
Conclusions/Significance: Genotypes of rs2580520 at 1p11.2 suggest that Chinese women may have different breast
cancer susceptibility loci, which may contribute to the development of breast cancer in this population.
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Introduction
Breast cancer is one of the most common cancers in the world
and becoming the first cancer-related killer to the women. It was
reported that the global burden of breast cancer in women was
substantial and on the increase, with 1.38 million new cases
diagnosed in 2008 [1,2]. As a developing country, breast cancer
incidence had been increasing 20% to 30% in China’s urban
registries in the past decade [3]. Numerous loci were identified to
have significantly association with the higher risk of breast cancer,
suggesting an important contribution of inherited factors to breast
cancer susceptibility [4–7].
Recently, a multistage genome-wide association study (GWAS)
of breast cancer identified a new breast cancer susceptible locus at
1p11.2 (the marker SNP: rs11249433) in populations of European
descent, which resides in a large linkage disequilibrium (LD)
block neighboring NOTCH2 and FCGR1B [4]. Subsequently,
another combined analysis of GWAS in breast cancer reported
the consistent result based on three GWAS of European descent
[8].
1p11.2 has been reported to have the underlying function in
mediating the cell growth and differentiation, and is regarded as a
region to mediate the intra-chromosomal recombination event [9].
Notch signaling at this region contributes a lot to cell
differentiation, survival and proliferation, and any alterations of
the pathway may lead to various disorders including human
malignancies [10–12]. FCGRs as the high affinity IgG required in
IgG immune responses may play a crucial role in linking humoral
and cellular branches of the immune system [13]. Based on its
functional importance, there were several published studies on this
gene family with immune disorders and breast cancer [14–17].
However, up to now, the association of genetic variants at
1p11.2 with breast cancer risk has not been evaluated in
populations of non-European descent. Specially, the minor allele
frequency (MAF) of rs11249433 is prominently lower in
populations of Chinese (0.022), Japanese (0.011) and African
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e21563(0.067) than that in population of European descent (0.450),
suggesting that there may be a heterogeneity of associations
between genetic variants in this region and breast cancer
susceptibility among different populations. Thus, to evaluate the
role of genetic variants at 1p11.2 with breast cancer susceptibility
in Chinese, we performed a fine mapping of approximately 277 kb
region at 1p11.2 with a two-stage case-control study including
1,792 breast cancer cases and 1,867 controls.
Materials and Methods
Ethics Statement
This study was approved by the institutional review board of
Nanjing Medical University. The design and performance of current
study involving human subjects were clearly described in a research
protocol. All participants were voluntary and would complete the
informed consent in written before taking part in this research.
Study subjects
A total of 1,792 breast cancer cases and 1,867 cancer-free
controls were included in this study. All subjects were genetically
unrelated ethnic Han Chinese women from Nanjing City and
surrounding regions in southeast China. Briefly, breast cancer
cases were recruited from the First Affiliated Hospital of Nanjing
Medical University, the Cancer Hospital of Jiangsu Province and
the Gulou Hospital, Nanjing, China, from January 2004 to April
2010. All the cases were newly diagnosed and histopathologically
confirmed without restrictions of age or histological type. Cancer-
free women controls were frequency-matched to the cases on age
and residential area (urban or rural), and were randomly selected
from a cohort of more than 30,000 participants in a community-
based screening program for non-infectious diseases conducted
from 2004 to 2006 in Jiangsu Province, China. A pretested
questionnaire was completed by trained interviewers to collect
information on demographic data, menstrual and reproductive
history, and environmental exposure history after the informed
consent was obtained from the participant. Approximately 5 ml of
venous blood was collected from each subject after the interview.
The estrogen receptor (ER) and progesterone receptor (PR) status
of breast cancer was abstracted from the medical records of
patients. In general, 878 cases and 900 controls were randomly
selected into the first fine-mapping stage, and the remaining 914
cases and 967 controls formed the validation stage.
SNP selection
Based on the public HapMap SNP database (phase II Nov 08,
on NCBI B36 assembly, dbSNP b126), we selected tagging SNPs
for the region approximately 277 kb from 120.7 to 121.1 Mb at
1p11.2 (the LD block where the marker SNP rs11249433 located)
with MAF $ 0.05 in Chinese Han population (CHB). Six SNPs
(rs2580520, rs4844616, rs12033387, rs6600745, rs4259688,
rs12743918) were selected based on an r
2 threshold of 0.8 by
the Haploview software. Using UCSC Genome Browser (http://
genome.ucsc.edu/cgi-bin/hgGateway), there were two different
locations (Feb.2009, GRCh37/hg19, dbSNP 132) of rs2580520,
referring to 1p11.2 and 1q32.1. We designed the primers and
probes for rs2580520 at 1p11.2. In addition, the previously
reported SNP rs11249433 which was significantly associated with
breast cancer risk in Caucasian and with MAF of 0.022 in CHB
was directly included in our study.
Genotyping assay
Genomic DNA was isolated from leukocyte pellets of venous
blood by proteinase K digestion and followed by phenol–
chloroform extraction. For the stage 1 samples, SNPs were
genotyped by using the TaqManH OpenArray
TM Genotyping
System (Applied Biosystems Inc.). Normalized human DNA
samples were loaded and amplified on customized arrays following
the manufacturer’s instructions. Each 48-sample array chip
contained two NTCs (no template controls). The overall call rate
was from 97.2% to 99.8% for all 7 SNPs in 878 breast cancer cases
and 900 controls. In the validation stage, the SNPs that were
significantly associated with breast cancer risk in stage 1 were
further genotyped for the stage 2 subjects with 914 breast cancer
cases and 967 controls by using the TaqMan assay on ABI PRISM
7900 HT platform (Applied Biosystems Inc.). Approximately equal
numbers of case and control samples were assayed in each 384-
well plate with two NTCs. Primers and probes were available
upon request. Genotyping was performed by blinding the case or
control status. Randomly selected 96 duplicates were examined by
the two platforms and the coincidence rate was 100%.
Statistical analyses
The x
2 test (for categorical variables) and student t test (for
continuous variables) were used to analyze the differences in
demographic characteristics, selected variables and frequencies of
the genotypes between the cases and controls. Odds ratios (ORs)
and 95% confidence intervals (CIs) were calculated by using
logistic regression model with adjustment for age, age at menarche
and menopausal status to estimate the associations between the
genotypes and breast cancer risk. Haplotype frequencies were
obtained from PHASE 2.1 program based on the observed
genotypes. We used CaTS 0.02 to perform the power estimation
of two stage association studies. All of the statistical analyses were
performed with Statistical Analysis System software (9.1.3; SAS
Institute, Cary, NC, USA).
Results
The distribution of selected characteristics between the overall
1,792 breast cancer cases and 1,867 cancer-free controls in two
stages are summarized in Table 1. Compared with the control
subjects, the breast cancer cases had a younger age at menarche
(P,0.0001) and an older age at first live birth (P,0.0001). On
average, older age at menopause achieved a borderline signif-
icance in breast cancer (P=0.051). Among breast cancer subjects,
803 (55.5%) cases were ER positive and 643 (44.5%) were
negative. Similarly, 810 (56.1%) cases were positive with PR while
634 (43.1%) were negative.
The genotype distributions of the 7 SNPs at 1p11.2 with MAF
and their associations with breast cancer risk are showed in
Table 2. The observed genotype frequencies for these seven SNPs
were all in agreement with Hardy–Weinberg equilibrium in the
controls (P=0.08, 0.724, 0.486, 0.189, 0.708, 0.289 and 0.997 for
rs2580520, rs4844616, rs12033387, rs11249433, rs6600745,
rs4259688 and rs12743918, respectively). In the single locus
analyses, two of the seven polymorphisms achieved significant
difference in the genotype distributions between cases and controls
(P=0.013, 0.014 for rs2582520 and rs4844616, respectively). In
stage 1, logistic regression analysis suggested that rs4844616 CT
genotype had a 23% reduction of breast cancer risk (OR = 0.77,
95% CI = 0.63–0.94, P=0.011), while the combined rs4844616
CT/TT genotypes had a 18% reduction (OR = 0.82, 95% CI =
0.68–1.00, P =0.045), when compared with the CC genotype.
Rs2580520GG genotype was associated with a non-significant
increased breast cancer risk in the recessive genetic model for stage
1 subjects (OR = 1.40, 95% CI = 0.93–2.09, P = 0.106).
Besides, the borderline significance of rs11249433 was also
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genotype compared with TT genotype (OR = 4.29, 95% CI =
0.90-20.47, P = 0.068). However, there were no obvious
evidences of significant associations between other five SNPs
(rs12033387, rs6600745, rs4259688, rs12743918) and breast
cancer risk.
Based on the results of stage 1, two promising SNPs (rs2580520
and rs4844616) that were significantly different of their genotype
distributions between the cases and controls were selected for the
stage 2 validation. In addition, we also select rs11249433 for
further validation to avoid the underestimation due to low MAF
and limited sample set of stage 1 (Table 2). We found the
association with rs4844616 was not validated (CT/TT vs. CC:
OR = 1.06, 95% CI = 0.87–1.29, P = 0.549 for stage 2 samples;
OR = 0.94, 95% CI = 0.82–1.07, P=0.341 for the combined
samples). However, no significant difference was observed for
rs11249433 genotypes between cases and controls (CT vs. TT:
OR = 1.17, 95% CI = 0.89–1.53, P=0.261 for the combined
samples; CC vs. TT: OR = 2.24, 95% CI = 0.65–7.65, P=0.200
for combined samples). Taking account of multiple comparisons,
we also used bonferroni adjustment to adjust the second stage
results, and P=7.1610
23 (0.05/6) was considered as the
significance threshold. Among all SNPs, only rs2580520 still had
a significantly increased risk of breast cancer in the recessive
genetic model (OR = 1.66, 95% CI = 1.16–2.36, P=0.005 for
stage 2 samples). Furthermore, Haplotype analysis was performed
for these three polymorphisms. As shown in Table 3, three
common haplotypes were identified to account for . 90% of all
conjectural haplotypes. Compared with the most common
haplotype CCT, no single haplotype was associated with the risk
of breast cancer.
In the stratified analysis, the association with rs2580520 in the
recessive genetic model was also evident among premenopausal
women (OR = 1.66, 95% CI = 1.15–2.39) and women with
older menarche age (OR = 1.54, 95% CI = 1.13–2.11), and
among the cases with ER positive (OR = 1.62, 95% CI = 1.17–
2.23) or PR positive (OR = 1.61, 95% CI = 1.17–2.21).
Nevertheless, no heterogeneity was observed between the stratified
subgroups (Table 4).
Discussion
To our knowledge, this is the first fine-mapping study in the
Chinese population to assess the association of polymorphisms at
1p11.2 with breast cancer risk. We evaluated one previously
reported SNP (rs11249433) and 6 common tagging SNPs
(rs2580520, rs4844616, rs12033387, rs660745, rs4259688 and
rs12743918) at 1p11.2 by fine mapping a 277 kb LD block. We
identified one SNP (rs2580520) as a marker SNP at this region
that was significantly associated with breast cancer risk in
Chinese.
Table 4. Stratified analysis on the associations between rs2580520 and risk of breast cancer.
Characteristics Case Control Recessive model
CC(%) CG(%) GG(%) CC(%) CG(%) GG(%) OR(95%CI)
a PP
b
Age
,50 563(63.2) 248(27.9) 79(8.9) 605(61.9) 312(31.9) 61(6.2) 1.53(1.06,2.20) 0.043 0.668
$50 553(62.1) 251(28.2) 86(9.7) 514(59.6) 303(35.2) 45(5.2) 1.63(1.10,2.41) 0.014
Menopausal status
Premenopausal 526(62.1) 242(28.6) 79(9.3) 589(61.4) 314(32.8) 56(5.8) 1.66(1.15,2.39) 0.007 0.520
Postmenopausal
c 474(62.5) 218(28.7) 67(8.8) 499(59.8) 288(34.5) 48(5.7) 1.39(0.93,2.06) 0.107
Age at menarche
,15 428(62.6) 191(27.9) 65(9.5) 234(59.9) 133(34.0) 24(6.1) 1.63(1.00,2.66) 0.050 0.848
$15 669(63.1) 302(28.5) 89(8.4) 879(61.0) 480(33.3) 82(5.7) 1.54(1.13,2.11) 0.007
Age at first live birth
,25 386(63.0) 165(26.9) 62(10.1) 521(57.3) 333(36.6) 55(6.1) 1.70(1.15,2.51) 0.008 0.467
$25 661(62.5) 311(29.5) 84(8.0) 569(64.6) 263(29.8) 49(5.6) 1.39(0.95,2.02) 0.091
ER status
ER+ 505(62.3) 215(26.9) 78(9.8) 1.62(1.17,2.23) 0.003 0.568
ER- 394(61.7) 190(29.7) 55(8.6) 1.41(0.99,2.00) 0.057
PR status
PR+ 503(62.3) 225(27.9) 79(9.8) 1.61(1.17,2.21) 0.004 0.585
PR- 392(62.4) 182(29.0) 54(8.6) 1.41(0.99,2.01) 0.055
aAdjusted by age, age at menarche, menopausal status where appropriate.
bp for heterogeneity.
cPostmenopausal status for natural menopause.
doi:10.1371/journal.pone.0021563.t004
Table 3. Haplotype Analysis of the Identified 3 SNPs.
Haplotype
a Cases(n=1792) Controls(n=1867) OR (95% CI)
CCT 1043(58.2%) 1103(59.1%) 1.00
GTT 314(17.5%) 351(18.8%) 1.06(0.88,1.26)
CTT 274(15.3%) 284(15.2%) 0.98(0.81,1.19)
Others 161(9.0%) 129(6.9%) 0.76(0.59,0.98)
aIn the order of rs2580520, rs484416 and rs11249433.
doi:10.1371/journal.pone.0021563.t003
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PLoS ONE | www.plosone.org 6 June 2011 | Volume 6 | Issue 6 | e21563Previous studies in Caucasian populations on 1p11.2 and breast
cancer susceptibility identified the marker SNP of rs11249433.
This SNP was 568kb to the transcription start site of NOTCH2,a
gene associated with insulin release, insulin sensitivity, obesity and
type 2 diabetes [18,19]. As NOTCH family members play a role
in a variety of developmental processes by controlling cell fate
decisions, more and more studies follow closely on the NOTCH
signaling pathway as one of the underlying mechanisms [10] and
candidate therapeutic targets for breast cancer [20]. However, the
SNP rs11249433 was heterogeneous among different ethnics, with
a common frequency of 0.425 in Caucasians and very low
frequency of 0.022 in CHB HapMap and 0.040 in our control
subjects. Unfortunately, because of the low frequency of
rs11249433 that leads to the low power (approximately 31%),
we did not find a significant association of this SNP with
susceptibility of breast cancer in this Chinese population (CT vs.
TT: OR = 1.17, 95% CI = 0.89–1.53, P = 0.261, CC vs. TT:
OR = 2.24, 95% CI = 0.65–7.65, P=0.200 for combined
samples). In fact, the heterozygote OR from combined stage is
highly consistent with of Thomas’s study [4]. Therefore, we cannot
exclude the limitation of power may hold back the statistically
significant to the true association.
With a two-stage fine mapping study at 1p11.2, we identified a
marker SNP rs2580520 in Chinese. Rs2580520 was in low LD
(pairwise r
2 = 0.005, Fig. 1) with rs11249433 in Chinese
population and no LD in European population (pairwise r
2 =
0.000). The MAF of rs2580520 was common in Chinese (0.178)
but extremely rare in European population (0.000), suggesting the
population specificity. This newly-identified marker SNP is located
in the intron of SRGAP2 (SLIT-ROBO Rho GTPase activating
protein 2) that has been proved to negatively regulate neuronal
migration and induce neurite outgrowth [21]. Using G2SBC
(Genes-to-Systems Breast Cancer) database (http://www.itb.cnr.
it/breastcancer/index.html), we found the SRGAP2 expression was
up regulated in multiple breast cancer cells. However, the exact
mechanism of the SRGAP2 in the development of breast cancer
still needs further investigation. As labeled in Figure 1, rs2580520
was located in an enhancer region but far from the NOTCH2 gene
(about 400kb to the transcription start site, UCSC genome
browser database, Build 36 assembly, hg18). It is recognized that
enhancer can increase the efficiency of transcription of the specific
genes even from far distance. Based on the position of rs2580520,
we conjectured that this SNP may regulate the upstream genes of
transcription starts by enhancer, such as FCGR1B or NOTCH2.
NOTCH2 expression was high in well-differentiated tumours but
low in poor-differentiated tumours which might play a tumour-
suppressive role in human breast cancer [11]. The direct relation
between FCGR1B and breast cancer was not reported, but FCGR
gene family was proved to do with breast cancer risk as mentioned
above [17]. Additionally, the position of rs2580520 at pericen-
tromeric regions may alter gene expression during cellular
differentiation or reprogramming, and therefore may promote
the normal cells into abnormal growth and differentiation which
eventually lead to tumors. Together, our results support
chromosome 1p11.2 as a susceptibility region for breast cancer
and emphasize the difference in genetic markers among different
ethnic populations [22].
In summary, our present results provide evidence that Chinese
women may have different breast cancer susceptibility loci at
1p11.2 and rs2580520 in this region was associated with genetic
susceptibility of breast cancer in Chinese population.
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